What is the recommended oral dose of salbutamol for children, including dosing by age and weight?

Oral Salbutamol Pediatric Dosing

For oral salbutamol in children, the standard dose is 0.1 mg/kg/dose three to four times daily, with typical fixed doses of 2 mg for children 2-6 years and 2-4 mg for children 6-14 years, though nebulized formulations are strongly preferred over oral tablets or syrup for acute asthma management. 1, 2

Important Context: Nebulized vs. Oral Formulations

The evidence provided focuses predominantly on nebulized (inhaled) salbutamol rather than oral formulations, which is the current standard of care. The FDA labeling and guidelines reference nebulization dosing, not oral tablets or syrup 3, 1. Oral salbutamol has largely been replaced by inhaled formulations in modern practice due to superior efficacy and reduced systemic side effects.

Oral Dosing by Age (When Used)

Children 2-6 Years

• 1-2 mg three times daily (every 8 hours) has been shown safe in this age group 4
• Start with 1 mg and may increase to 2 mg based on response 4

Children 6-14 Years

• 4 mg four times daily is the preferred dose, administered as syrup (2 mg/5 mL) 2
• The 4 mg syrup dose reaches maximum effect at 4 hours and lasts 6 hours 2
• Doses of 2 mg, 4 mg, and 6 mg were studied, with 4 mg providing optimal efficacy-to-side-effect ratio 2

Weight-Based Dosing

• 0.1 mg/kg/dose three to four times daily is the general weight-based approach 5, 2

Critical Caveat: Nebulized Formulations Are Preferred

For acute asthma management, nebulized salbutamol at 0.15 mg/kg (minimum 2.5 mg) is the recommended route, not oral administration 3. The nebulized route provides:

• Direct delivery to airways
• Faster onset of action
• Reduced systemic side effects compared to oral formulations

Nebulized Dosing (Standard of Care)

For Children ≥2 Years and ≥15 kg

• 2.5 mg (one vial of 0.083% solution) three to four times daily via nebulization 1
• Delivered over 5-15 minutes with appropriate flow rate 1

For Children <15 kg

• Use 0.5% concentration solution to allow dosing <2.5 mg 1

Acute Exacerbations (Age 5 and Similar)

• 0.15 mg/kg (minimum 2.5 mg) every 20 minutes for three doses initially 3
• Maintenance: 0.15-0.30 mg/kg (use 2.5 mg) every 1-4 hours as needed for mild-moderate exacerbations 3
• Severe exacerbations: continuous nebulization at 0.5 mg/kg/hour 3

Safety Considerations

Common Side Effects

• Tremors are the most frequently reported adverse effect with oral salbutamol 5
• Tachycardia and increased heart rate, particularly with syrup formulation 2
• Hypokalemia with repeated dosing (20-25% decline in serum potassium) 1

Age-Specific Safety

• Safety and effectiveness established for children ≥2 years 1
• Safety not established for children <2 years for oral/nebulized formulations 1
• However, recent meta-analysis shows inhaled salbutamol can be safely used in children <2 years with acute wheeze, with MDI being safer than nebulized formulation 6

Contraindications and Precautions

• Use with caution in cardiovascular disorders, arrhythmias, hypertension, convulsive disorders, hyperthyroidism, or diabetes 1
• Do not use concomitantly with other sympathomimetic bronchodilators 1
• Extreme caution with MAO inhibitors or tricyclic antidepressants 1

Common Pitfalls to Avoid

• Do not reduce nebulized dose below 2.5 mg minimum even if weight-based calculation suggests lower dose 3
• Do not use oral salbutamol for acute exacerbations—nebulized or MDI with spacer is the appropriate route 3
• Do not exceed recommended frequency without medical consultation; worsening symptoms requiring increased dosing indicate need for reassessment 1
• Oral formulations have inferior bioavailability and slower onset compared to inhaled routes 2

Clinical Bottom Line

While oral salbutamol dosing is 0.1 mg/kg/dose (or fixed doses of 1-4 mg based on age) three to four times daily, this route is outdated for asthma management. Current practice strongly favors nebulized salbutamol (2.5 mg for children ≥15 kg) or MDI with spacer (4-8 puffs) for both acute and maintenance therapy 3, 1. Oral formulations may only be considered in resource-limited settings where inhaled delivery is unavailable.